Why GLP-1 weight loss pills could spark big pharma's next rally

The shift from injectable treatments to oral GLP-1 weight-loss pills is setting the stage for a major turning point across big pharma, led by the battle between Novo Nordisk and Eli Lilly. As adoption rates climb globally, this booming drug class could be poised to reshape healthcare earnings while sending ripple effects through the broader consumer economy. Today's watchlist: Novo Nordisk, Judo Bank Check out these stocks: www.moomoo.com/quote